Inhibikase Therapeutics logo
Inhibikase Therapeutics IKT
$ 1.69 3.68%

Annual report 2025
added 03-26-2026

report update icon

Inhibikase Therapeutics Cash Flow 2011-2026 | IKT

Annual Cash Flow Inhibikase Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-27.8 M -19.1 M -18.1 M -17.4 M -14.3 M -1.13 M - - - - - - - - -

Depreciation & Amortization

60.5 K 26.3 K 177 K 6.72 K - - - - - - - - - - -

Accounts Payables

1.16 M 943 K 647 K 1.15 M 1.09 M - - - - - - - - - -

Accounts Receivables

- - - 39.9 K 110 K - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Inhibikase Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -4.1 M - - - -3.87 M - - - -5.97 M - -13.8 M -8.29 M -3.93 M - -10.2 M -8.18 M -3.93 M - -183 K -258 K -255 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

23.7 K 24.2 K 12.7 K - 6.57 K 6.57 K 6.57 K - 6.57 K 159 K 5.04 K - 1.68 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

621 K 2.7 M 1.69 M 943 K 2.53 M 1.34 M 1.29 M 647 K 735 K 754 K 959 K 1.15 M 781 K 860 K 806 K 1.09 M 554 K 897 K 715 K 1.72 M 1.72 M 1.72 M 1.72 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

- - - - - - - - - 79.6 K 64.5 K 39.9 K 13.8 K 6.55 K 48 K 110 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Inhibikase Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 18.06 - $ 28.2 B japanJapan
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.44 -0.46 % $ 909 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Protara Therapeutics Protara Therapeutics
TARA
$ 5.03 -3.08 % $ 215 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 67.0 -0.3 % $ 2.8 B usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Theravance Biopharma Theravance Biopharma
TBPH
$ 14.9 -1.91 % $ 750 M cayman-islandsCayman-islands
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.2 -6.97 % $ 306 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 51.31 -2.65 % $ 8.08 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 14.64 -2.2 % $ 574 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.07 -2.29 % $ 21.9 M israelIsrael
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 28.76 -3.43 % $ 32.9 B israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Equillium Equillium
EQ
$ 2.03 -1.46 % $ 116 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 23.81 1.51 % $ 641 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 46.38 -2.45 % $ 4.17 B schweizSchweiz